Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Yonesaka, Kimio; Zejnullahu, Kreshnik; Okamoto, Isamu; Satoh, Taroh; Cappuzzo, Federico; Souglakos, John; Ercan, Dalia; Rogers, Andrew; Roncalli, Massimo; Takeda, Masayuki; Fujisaka, Yasuhito; Philips, Juliet; Shimizu, Toshio; Maenishi, Osamu; Cho, Yonggon; Sun, Jason; Destro, Annarita; Taira, Koichi; Takeda, Koji; Okabe, Takafumi; Swanson, Jeffrey; Itoh, Hiroyuki; Takada, Minoru; Lifshits, Eugene; Okuno, Kiyotaka; A. Engelman, Jeffrey; A. Shivdasani, Ramesh; Nishio, Kazuto; Fukuoka, Masahiro; Varella-Garcia, Marileila; Nakagawa, Kazuhiko; A. Jänne, Pasi

doi:10.1126/scitranslmed.3002442

Public

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Shared by NobleBlocks on Sep 7, 2011 • 12:00 AM UTC

Authors:

Kimio Yonesaka

Kreshnik Zejnullahu

Isamu Okamoto

Abstract

Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1/2-stimulated growth.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!